Drugs / [212Pb]VMT-α-NET
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06148636 | Nov 2023 → Dec 2026 expected | carcinoid tumor, lung neuroendocrine neoplasm, pancreatic neuroendocrine tumor | David Bushnell | Active not recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05636618 | Sep 2023 → Nov 2029 expected | bronchial endocrine tumor, digestive system neuroendocrine neoplasm, meningioma, paraganglioma +1 | Perspective Therapeutics | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 10
| Date | Issuer | Release |
|---|---|---|
| 2026-07-28 | Perspective Therapeutics | Regulatory Perspective Therapeutics Receives European Orphan Medicinal Product Designation for [212Pb]VMT-α-NET in GEP-NETs perspectivetherapeutics.com ↗ |
| 2026-05-21 | Perspective Therapeutics | Results Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma perspectivetherapeutics.com ↗
Updated [212Pb]VMT-α-NET interim efficacy (n=25) and safety data (n=68) as of April 17, 2026, were consistent with previously disclosed findings at AACR as of March 4, 2026 with continued deepening of responses; additional updates expected in late 2026 |
| 2026-04-20 | Perspective Therapeutics | Results Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in Its Ongoing Phase 1/2a Clinical Trial at the 2026 AACR Annual Meeting perspectivetherapeutics.com ↗
today announced updated interim results from its ongoing Phase 1/2a clinical trial of [212Pb]VMT-α-NET in patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing neuroendocrine tumors (NETs) as part of a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026. |
| 2026-01-09 | Perspective Therapeutics | Results Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial at the 2026 ASCO Gastrointestinal Cancers Symposium perspectivetherapeutics.com ↗
Interim results with a data cut-off date of December 10, 2025 formed the basis of the ASCO-GI update. |
| 2025-10-20 | Perspective Therapeutics | Results Perspective Therapeutics Presents Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the ESMO Congress 2025 perspectivetherapeutics.com ↗
Interim results with a data cut-off date of September 12, 2025 formed the basis of the ESMO presentation. |
| 2025-06-21 | Perspective Therapeutics | Results Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting perspectivetherapeutics.com ↗
The findings of the study suggest that: |
| 2023-09-12 | Perspective Therapeutics | Results Perspective Announces Presentation of Positive Early Clinical Data for VMT-α-NET at the 36th Annual Congress of the European Association of Nuclear Medicine perspectivetherapeutics.com ↗
Ten patients who failed at least 1 prior line of standard of care therapy have received [212Pb]VMT-α-NET therapy to date, with initial responses observed in 7 of 9 evaluable patients. |
| 2023-09-11 | Perspective Therapeutics | Results Perspective Therapeutics Presents Positive Preclinical Alpha Particle Therapy Data at the World Molecular Imaging Congress 2023 and the 36th Annual Congress of the European Association of Nuclear Medicine perspectivetherapeutics.com ↗
Administrations of the three fractionated doses of [212Pb]VMT-α-NET resulted in a 70% complete response rate and an 80% survival rate at 120 days. |
| 2023-08-30 | Perspective Therapeutics | Results Perspective Therapeutics to Present at the World Molecular Imaging Congress 2023 perspectivetherapeutics.com ↗
We demonstrated the significant therapeutic benefit of [212Pb]VMT-α-NET in a mouse model and the potential for high probability of complete response. |
| 2023-08-28 | Perspective Therapeutics | Results Perspective Therapeutics to Present Clinical and Preclinical Data at the 36th Annual Congress of the European Association of Nuclear Medicine perspectivetherapeutics.com ↗
The data showed that fractionated doses of [212Pb]VMT-α-NET provided greater benefit than single dose administration of [212Pb]VMT-α-NET. |
All press releases naming this drug 12 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [212Pb] VMT-α-NET | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06148636 ↗ |
| Known as | 212Pb (212-lead) VMT-α-NET | “The study involves two treatments with 212Pb (212-lead) VMT-α-NET.” NCT06148636 ↗ |
| Modality | Peptide | “peptide-radiopharmaceuticals” NCT05636618 ↗ |
| Route | Intravenous | “administered by intravenous infusion” NCT05636618 ↗ |